The Triage BNP test is intended for use with Beckman Coulter Immunoassay Systems (Access, Access 2, Synchron LXi 725 and UniCel Dxl 800) for the In Vitro quantitative measurement of B-type natriuretic peptide (BNP) in plasma specimens using EDTA as the anticoagulant. The test is intended to be used as an aid in the diagnosis and assessment of severity of congestive heart failure (also referred to as heart failure). The test also is used for the risk stratification of patients with acute coronary syndromes and for the risk stratification of patients with heart failure.

Device Description

The Triage® BNP test is intended for use with Beckman Coulter Immunoassay Systems (Access, Access 2, Synchron LXi 725 and UniCel Dxl 800) for the In Vitro quantitative measurement of B-type natriuretic peptide (BNP) in plasma specimens using EDTA as the anticoagulant.

AI/ML Overview

The provided text is a 510(k) summary for the Triage BNP Test for the Beckman Coulter Immunoassay Systems. It primarily focuses on demonstrating substantial equivalence to previously cleared devices rather than describing a new study with explicit acceptance criteria and performance data.

Therefore, many of the requested details about acceptance criteria, specific study design, sample sizes, ground truth establishment, and expert involvement are not present in the provided document. The document refers to prior 510(k) clearances and "various peer-reviewed publications" without detailing new studies.

Here's a breakdown based on the available information:

1. Table of Acceptance Criteria and Reported Device Performance

This information is not present in the provided document. The 510(k) summary focuses on demonstrating substantial equivalence to predicate devices (K033383, K021317, K051787, R021011, R031170) based on identical principles, reagents, and procedures, rather than presenting new performance data against specific acceptance criteria.

2. Sample size used for the test set and the data provenance

This information is not present in the provided document. While it mentions "various peer-reviewed publications" describing the utility of BNP measurements, it does not detail a specific test set or its provenance for this submission.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

This information is not present in the provided document.

4. Adjudication method for the test set

This information is not present in the provided document.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

An MRMC study is not mentioned and is not relevant as this is a quantitative immunoassay device, not an imaging or AI-assisted diagnostic device where human reader performance would be a primary focus.

6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done

This is an in vitro diagnostic immunoassay. Its performance is inherently "standalone" in the sense that it provides a quantitative measurement. The document implies that the device's performance is demonstrated by its substantial equivalence to previously cleared devices, which would have undergone performance validation studies. However, the details of those specific studies are not provided in this document.

7. The type of ground truth used

This information is not explicitly stated for any new study in this document. For previous clearances of similar BNP tests, ground truth for diagnosis/assessment of heart failure would typically involve clinical diagnosis by cardiologists, imaging (e.g., echocardiography), and patient outcomes data regarding hospitalization or death. The document does state: "Higher BNP concentrations or the lack of a decrease in the BNP concentration from hospital admission to discharge indicate an increased risk of hospitalization or death in patients with heart failure," implying clinical outcomes as the ultimate ground truth for risk stratification.

8. The sample size for the training set

This information is not present as this is not an AI/Machine Learning device that would have a "training set" in that context. The device is a chemical immunoassay system.

9. How the ground truth for the training set was established

Not applicable (see point 8).

Summary

{0}------------------------------------------------

K052789

510(k) Summary of Safety and Effectiveness II.

In accordance with the provisions of Section 4 of the Safe Medical Devices Act of 1990 and 21 CFR 807.92, the following summary is provided. Biosite requests that this document be maintained CONFIDENTIAL until such time that the product is cleared by the Food and Drug Administration via the 510(k) process and in accordance with the provisions of the Act.

A. Name and Address of Submitter

Company Name:Address:	Biosite Incorporated9975 Summers Ridge RoadSan Diego, CA 92121
Telephone:	(858) 805-2719
Fax:	(858) 695-3823
Contact Person:	Rachael S. Williamson, MS, RAC
Date Summary Prepared:	January 4, 2006

B. Product

Triage® BNP Test for the Beckman Coulter Immunoassay Systems

C. Predicate Devices

Biosite Triage BNP Test for the Beckman Coulter Immunoassay Systems (K033383) Biosite Triage BNP Test (K021317 and K051787)

Biosite Triage BNP Test (R021011 and R031170)

D. Device Description and Intended Use

{1}------------------------------------------------

E. Summary of Substantial Equivalence

Various peer-reviewed publications have described the utility of BNP measurements as an aid in the risk stratification of patients with heart failure. Higher BNP concentrations or the lack of a decrease in the BNP concentration from hospital admission to discharge indicate an increased risk of hospitalization or death in patients with heart failure.

The device and test method described in this Premarket Notification is identical in principle, reagents and procedure to its predecessor, the currently marketed Triage BNP Test for the Beckman Coulter Immunoassay (K033383).

Moreover, the Triage BNP Test (K051787) serves as the predicate method for the use of a circulating biomarker to provide prognostic information in patients with heart failure. The use of the Triage BNP Test for the Beckman Coulter Immunoassay Systems as an aid in the risk stratification of patients with heart failure is substantially equivalent to the predicate method.

F. Conclusion

In conclusion, the data presented in this Premarket Notification demonstrate the substantial equivalence of the Triage BNP Test for the Beckman Coulter Immunoassay Systems to currently marketed devices which have been reviewed and cleared through the 510(k) Premarket Notification process. Such data are a critical element in establishing the fundamental safety and effectiveness of the device and its appropriateness for commercial distribution.

{2}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services (HHS). The logo features a stylized depiction of an eagle or bird with three curved lines forming its wing or body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the bird symbol.

Public Health Service

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

JAN 2 3 2006

Ms. Rachael Williamson Regulatory Affairs Specialist Biosite Incorporated 9975 Summers Ridge Road San Diego, CA 92121

Re: K052789

Trade/Device Name: Triage BNP Test for the Beckman Coulter Immunoassay Systems Regulation Number: 21 CFR 862.1117 Regulation Name: B-type natriuretic peptide test system Regulatory Class: Class II Product Code: NBC Dated: September 30, 2005 Received: October 31, 2005

Dear Ms. Williamson

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

{3}------------------------------------------------

Page 2 --

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Alberto G. A.

Alberto Gutierrez, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Indications for Use

510(k) Number (if known): K052789

Device Name:

Triage BNP Test for the Beckman Coulter Immunoassay Systems

Indications For Use:

i Prescription Use AND/OR (Per 21 CFR 801.109)

Over-The-Counter Use (Per 21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Ann Chappie
Division Sign-Off

Division Sign-Off

Office of In Vitro Diagnostic Device Evaluation and Safety

-Page 1 of

510(k)

Regulation Number and Section

§ 862.1117 B-type natriuretic peptide test system.

(a)
Identification. The B-type natriuretic peptide (BNP) test system is an in vitro diagnostic device intended to measure BNP in whole blood and plasma. Measurements of BNP are used as an aid in the diagnosis of patients with congestive heart failure.(b)
Classification. Class II (special controls). The special control is “Class II Special Control Guidance Document for B-Type Natriuretic Peptide Premarket Notifications; Final Guidance for Industry and FDA Reviewers.”